स्वास्थ्य
Reimbursement approval approaching for Carmat artificial heart technology
BFM Business
मुख्य बिंदु
- Carmat has obtained data proving the effectiveness of its artificial heart technology.
- The reimbursement approval (remboursement) process from the French Social Security may begin.
- This approval will change patients' access to the device and the company's commercial roadmap.
French artificial heart specialist Carmat has obtained data proving its technologies work. This development could lead to the company obtaining reimbursement approval from the French Social Security (Assurance Maladie) for its products.
Carmat, a pioneer in artificial heart development, has crossed a commercial and medical threshold by gathering clinical evidence. If reimbursement approval comes, patients' access to these life-saving devices will be significantly eased.
प्रतिक्रिया दें
इस खबर के बारे में पूछें
उत्तर केवल इस खबर से AI द्वारा।
अक्सर पूछे जाने वाले प्रश्न
- In which field is Carmat a specialized company?
- Carmat is a French medical technology company developing total artificial heart systems.
- What does reimbursement approval (remboursement) mean?
- It means the French health insurance (Assurance Maladie) covers the cost of the device, meaning patients can obtain the device for free or at a very low cost.
- When will this development affect patients?
- The article does not give a specific date; it states the approval process has begun, but the timing of the official decision has not been disclosed.
यह एआई द्वारा बनाया गया संक्षिप्त सारांश है। पूरी खबर स्रोत पर है।
स्रोत पर पूरी खबर पढ़ेंbfmtv.comहम अपनी सामग्री कैसे बनाते हैं →संबंधित समाचार
विश्व